Biocon clears path for cancer drug launch

Benchmarks Nifty22,622.70-99.25FEATURED FUNDS★★★★★UTI Aggressive Hybrid Fund Regular Plan-Growth5Y Return8.71 % Invest NowFEATURED FUNDS★★★★★Motilal Oswal Midcap Fund Direct-Growth5Y Return19.29 % Invest NowEnter search text:

The Economic Times daily newspaper is available online now. Read Today's Paper Biocon clears path for cancer drug launchPTILast Updated: Oct 15, 2026, 12:24:00 AM ISTSynopsis

Biocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing legal disputes between the two companies in jurisdictions such as the US and Canada. Under the terms, Biocon can launch Pebrilzo in the EU and UK by early 2027 and in the US by Q3 of 2028. Other global launches are planned between 2026 and 2028, depending on regulatory approvals.

Listen to this article in summarized format

Loading...×Biocon on Wednesday said it has entered into a global settlement and license agreement with Genentech for breast cancer drug Pebrilzo, its biosimilar to the reference product Perjeta (Pertuzumab). The patent settlement agreement resolves all pending disputes between the two companies across multiple jurisdictions, including the US and Canada, the biopharmaceutical company said in a regulatory filing on Wednesday

Under the terms of the agreement, Biocon is cleared to launch Pebrilzo in the European Union and UK in the first quarter of calendar year (CY) 2027, followed by a launch in US in Q3 of CY 2028. For other world markets, the launch is slated for 2026-28, or earlier under certain circumstances.

Also read: Biocon founder says India must shift pharma industry from generics to innovation-led growth

The company said product launches across all countries and regions remain subject to regulatory approvals. Other terms of the settlement remain confidential.

Pebrilzo is a biosimilar medicine with Pertuzumab as its active substance and is indicated for the treatment of HER2-positive breast cancer across multiple disease stages.
Add as a Reliable and Trusted News Source Add Now!
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onbioconBiocon cancer drug launchPebrilzo breast cancer drugGenentech patent settlementbiosimilar Pertuzumabcancer medicinesbiocon newsBiocon

(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)

...moreless
(You can now subscribe to our Economic Times WhatsApp channel)
Read More News onbioconBiocon cancer drug launchPebrilzo breast cancer drugGenentech patent settlementbiosimilar Pertuzumabcancer medicinesbiocon newsBiocon

(Catch all the Business News, Breaking News and Latest News Updates on The Economic Times.)

...moreless

Stories you might be interested in